IMBRIC MOBILITY
IMBRIC MOBILITY is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
Sponsor Swedish Orphan Biovitrum AB (publ)
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for IMBRIC MOBILITY?
The 2026-10-09 snapshot links IMBRIC MOBILITY to 2 distinct CTIS trials. Recorded services include Taxi Service for Spanish patients to attend their clinical trial appointments, Taxi services for participants in Spain.. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for IMBRIC MOBILITY?
The most frequently recorded therapeutic areas are Nephrology. Recorded phases include Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to IMBRIC MOBILITY conducted?
The linked trials record locations in 8 countries, including Belgium, Spain, France, Austria, Czechia. These are trial locations, not confirmed office locations or countries where IMBRIC MOBILITY delivered services.
What can this page tell me about IMBRIC MOBILITY's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under IMBRIC MOBILITY. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- IMBRIC MOBILITY S.L.
- Imbric Mobility S.L.